MAGNETOM Cima.X Fit

The MAGNETOM Cima.X Fit is an advanced magnetic resonance diagnostic device intended to produce detailed anatomical and functional images for diagnostic support, featuring the syngo MR XA61A software platform and updated hardware components. Its operational methodology combines fundamental magnetic resonance principles with innovative technologies like AI-driven image reconstruction (e.g., Deep Resolve Boost), advanced sequences such as MR Fingerprinting, and motion reduction techniques like SAMER, all validated through rigorous nonclinical testing and supported by relevant clinical publications for specific applications.

The MAGNETOM Cima.X Fit, equipped with syngo MR XA61A software, is a magnetic resonance diagnostic device (MRDD) designed to generate a comprehensive range of images, including cross-sectional (transverse, sagittal, coronal, oblique) and spectroscopic views, to visualize the internal structure and function of the head, body, or extremities. Its intended use includes deriving physical parameters from these images and spectra to assist physicians in diagnosis, with the option of using contrast agents and supporting imaging during MR-compatible interventional procedures. The system features new hardware components like a 3D camera and modified elements such as the gradient coil, body coil, host computers, and cooling system, all integrated to enhance its diagnostic capabilities. This device introduces several new and modified software applications, notably leveraging artificial intelligence for image processing. Key innovations include 'Deep Resolve Boost' for HASTE and EPI Diffusion sequences, 'Deep Resolve Sharp,' 'Open Recon' for customizable reconstruction, 'Ghost reduction (DPG),' 'SAMER' for motion correction, and 'MR Fingerprinting.' The system's performance and safety were validated through extensive nonclinical testing, encompassing software verification, image quality assessments using sample clinical images, hardware bench tests, and adherence to safety standards. AI features were trained and validated on large datasets covering a broad range of body parts and contrasts, demonstrating improvements in image metrics such as PSNR and SSIM, and evaluated through visual comparisons for aspects like aliasing artifacts, image sharpness, and denoising levels, though specific demographic data for AI training was not recorded due to privacy reasons; no new clinical tests were conducted, but relevant clinical publications were referenced for specific features.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the new 'Deep Resolve Boost EPI Diffusion' and 'Deep Resolve Boost HASTE' features, particularly regarding image quality and diagnostic accuracy, compare quantitatively against traditional reconstruction methods in diverse patient populations?; What is the specific impact of the modified gradient coil and body coil on image signal-to-noise ratio (SNR) and spatial resolution, especially for advanced applications like MR Fingerprinting?; Could the 'Open Recon' platform be detailed further in terms of its flexibility for researchers to implement custom reconstruction algorithms, and what are the computational overheads associated with it?; Given the reliance on AI for features like Deep Resolve, what strategies are in place to monitor and mitigate potential biases in the AI models, especially since demographic data (gender, age, ethnicity) was not recorded during the collection of training/validation datasets?; How does the 'SAMER' (Scout accelerated motion estimation and reduction) feature perform in real-world clinical scenarios with significant patient motion, and what are its limitations compared to other motion correction techniques?